HTG Molecular Diagnostics and Centre Léon Bérard Enter Into Molecular Profiling Research Agreement
April 17 2017 - 8:00AM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments, reagents, and services for molecular profiling
applications, announced that it has entered into a research
agreement with Centre Léon Bérard, which provides the framework for
molecular profiling studies aimed to advance precision medicine.
The initial project utilizes the HTG EdgeSeq Oncology
Biomarker Panel to retrospectively characterize immunologic
profiles from advanced malignant tumor samples collected in the
ProfiLER study (ClinicalTrials.gov identifier NCT01774409).
“We believe this immunogenic profiling of tumors,
led by Dr. Pierre Saintigny within the Department of Translational
Research and Innovation, will allow us to identify biomarkers with
a potential predictive value and to determine if some genetic
disorders are linked to immunity status alterations,” said Pr.
Jean-Yves Blay, M.D., Ph.D., Director of Centre Léon Bérard. Centre
Léon Bérard, located in Lyon, France, is a member of the French
Federation of Cancer Centers and UNICANCER, which brings together
20 French hospitals that specialize in the treatment of cancer
patients.
“We are thrilled to be working with the Centre Léon
Bérard in the fight against cancer,” said Jean Claude Gerard Vice
President of European Operations for HTG. “Our HTG EdgeSeq
chemistry is well suited for the initial project because it will
allow Dr. Saintigny and team to perform molecular profiling on
small FFPE samples, and we believe the project sets the stage for
future diagnostic opportunities arising from this
collaboration.”
About HTG:
Headquartered in Tucson, Arizona, the mission of
HTG Molecular Diagnostics (HTG) is to empower precision medicine at
the local level. In 2013 the company commercialized its first
instrument platform and a portfolio of RNA assays that leveraged
HTG's original proprietary nuclease protection chemistry.
Continuous improvement led to the 2014 launch of the company’s HTG
EdgeSeq product line, which automates sample and targeted library
preparation for next-generation sequencing. Additional information
is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the anticipated benefits or results of our agreement with
Centre Léon Bérard, the capabilities of our technology, and our
ability to advance precision medicine with our research partners or
otherwise. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements necessarily contain these
identifying words. These forward-looking statements are based upon
management's current expectations, are subject to known and unknown
risks, and involve assumptions that may never materialize or may
prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation, risks associated with
the process of developing and commercializing diagnostic products,
our ability to achieve and sustain sufficient market acceptance,
and the capabilities of our product and service solutions to keep
pace with rapidly changing technology and customer requirements.
These and other factors are described in greater detail in our
filings with the Securities and Exchange Commission, including
without limitation our Annual Report on Form 10-K for the Year
ended December 31, 2016. All forward-looking statements contained
in this press release speak only as of the date on which they were
made, and we undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2023 to Apr 2024